Elastic NV vs Heron Therapeutics Inc — how do they compare? Elastic NV trades at $95.26 (market cap $9.77B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Elastic NV is far larger — about 132× Heron Therapeutics Inc's market cap, and Elastic NV is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and Heron Therapeutics Inc for 35 Days on average.
| ESTC | HRTX | |
|---|---|---|
Market Cap | $9.77B | $74.04M |
Volume | 945,514 | 3,668,095 |
Sector | Technology | Health |
52-Week High | $99.91 | $1.49 |
52-Week Low | $43.30 | $0.27 |
Typical Hold Time | 10 Days | 35 Days |
Enterprise Value | $8.91B | $180.78M |
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $93.1, down 1.59% on the day, with a bullish technical outlook and strong earnings beats in recent quarters. The company shows robust revenue growth, improving profitability into 2026, and positive sentiment from analysts, with 22 buy ratings and no sells. Recent product launches, including AI-driven metrics and serverless vector database offerings, highlight innovation in its observability and search platforms.
The stock presents a growth opportunity driven by product innovation and expanding profit margins, but risks include high valuation multiples and competitive pressures in the enterprise software sector. Analyst consensus targets $79.50, below the current price, suggesting cautious optimism amid execution risks and market volatility.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →